UNC Lineberger, Gillings Biostatistics, and the Translational Breast Cancer Research Consortium have officially launched the $28 million ARPA-H ADAPT platform to reinvent metastatic breast cancer trials. Dr. Naim Rashid co-leads the analytics core, delivering a Bayesian adaptive design that learns from each participant’s longitudinal ctDNA, imaging, and clinical data in real time. The study will enroll 500 participants across partner sites beginning in 2025 and serves as a national model for precision medicine infrastructure.

Gillings News coverage: “ARPA-H awards $28M to UNC team to build adaptive breast cancer trial”.